# Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer

> **NCT06700603** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Rui-hua Xu, MD, PhD** · enrollment: 48 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate

## Key facts

- **NCT ID:** NCT06700603
- **Lead sponsor:** Rui-hua Xu, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-20
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06700603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06700603, "Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06700603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*